前收市價 | 1.2000 |
開市 | 1.2000 |
買盤 | 0.0000 |
賣出價 | 4.6000 |
拍板 | 815.00 |
到期日 | 2024-06-21 |
今日波幅 | 1.2000 - 1.2000 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 13 |
Regeneron (REGN) maintains momentum on the back of Dupixent profits and efforts to develop oncology portfolio despite near-term challenges.
There hasn't been a new COPD treatment in years. But Regeneron stock analysts are closely watching a pair of key FDA decisions.
Regeneron stock joined the 1,000-club this month as enthusiasm grows for its blockbuster drug, Dupixent, in COPD treatment.